vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and GREENLIGHT CAPITAL RE, LTD. (GLRE). Click either name above to swap in a different company.

GREENLIGHT CAPITAL RE, LTD. is the larger business by last-quarter revenue ($210.3M vs $121.8M, roughly 1.7× Core Laboratories Inc.). GREENLIGHT CAPITAL RE, LTD. runs the higher net margin — 23.4% vs 4.2%, a 19.2% gap on every dollar of revenue. On growth, GREENLIGHT CAPITAL RE, LTD. posted the faster year-over-year revenue change (48.3% vs -1.4%). Over the past eight quarters, GREENLIGHT CAPITAL RE, LTD.'s revenue compounded faster (4.8% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Greenlight Capital is an American hedge fund founded in 1996 by David Einhorn. Greenlight invests primarily in publicly traded North American corporate debt offerings and equities. Greenlight is most notable for its short selling of Lehman stock prior to Lehman Brothers' collapse in 2008 and the $11 million fine they received in January 2012 for insider trading in the UK. Einhorn remains the fund's manager.

CLB vs GLRE — Head-to-Head

Bigger by revenue
GLRE
GLRE
1.7× larger
GLRE
$210.3M
$121.8M
CLB
Growing faster (revenue YoY)
GLRE
GLRE
+49.7% gap
GLRE
48.3%
-1.4%
CLB
Higher net margin
GLRE
GLRE
19.2% more per $
GLRE
23.4%
4.2%
CLB
Faster 2-yr revenue CAGR
GLRE
GLRE
Annualised
GLRE
4.8%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
GLRE
GLRE
Revenue
$121.8M
$210.3M
Net Profit
$5.1M
$49.3M
Gross Margin
Operating Margin
1.5%
Net Margin
4.2%
23.4%
Revenue YoY
-1.4%
48.3%
Net Profit YoY
279.7%
EPS (diluted)
$0.11
$1.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
GLRE
GLRE
Q1 26
$121.8M
Q4 25
$138.3M
$210.3M
Q3 25
$134.5M
$146.1M
Q2 25
$130.2M
$160.1M
Q1 25
$123.6M
$213.3M
Q4 24
$129.2M
$141.8M
Q3 24
$134.4M
$188.0M
Q2 24
$130.6M
$174.9M
Net Profit
CLB
CLB
GLRE
GLRE
Q1 26
$5.1M
Q4 25
$4.9M
$49.3M
Q3 25
$14.2M
$-4.4M
Q2 25
$10.6M
$329.0K
Q1 25
$-154.0K
$29.6M
Q4 24
$7.4M
$-27.4M
Q3 24
$11.7M
$35.2M
Q2 24
$9.0M
$8.0M
Gross Margin
CLB
CLB
GLRE
GLRE
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
CLB
CLB
GLRE
GLRE
Q1 26
1.5%
Q4 25
11.5%
Q3 25
15.6%
Q2 25
11.7%
Q1 25
3.6%
Q4 24
11.0%
Q3 24
14.7%
Q2 24
12.3%
Net Margin
CLB
CLB
GLRE
GLRE
Q1 26
4.2%
Q4 25
3.6%
23.4%
Q3 25
10.6%
-3.0%
Q2 25
8.2%
0.2%
Q1 25
-0.1%
13.9%
Q4 24
5.7%
-19.3%
Q3 24
8.7%
18.7%
Q2 24
6.9%
4.6%
EPS (diluted)
CLB
CLB
GLRE
GLRE
Q1 26
$0.11
Q4 25
$0.11
$1.43
Q3 25
$0.30
$-0.13
Q2 25
$0.22
$0.01
Q1 25
$0.00
$0.86
Q4 24
$0.15
$-0.78
Q3 24
$0.25
$1.01
Q2 24
$0.19
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
GLRE
GLRE
Cash + ST InvestmentsLiquidity on hand
$22.8M
$111.8M
Total DebtLower is stronger
$4.7M
Stockholders' EquityBook value
$275.1M
$708.0M
Total Assets
$587.7M
$2.2B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
GLRE
GLRE
Q1 26
$22.8M
Q4 25
$22.7M
$111.8M
Q3 25
$25.6M
$68.8M
Q2 25
$31.2M
$82.4M
Q1 25
$22.1M
$47.5M
Q4 24
$19.2M
$64.7M
Q3 24
$21.5M
$54.6M
Q2 24
$17.7M
$52.2M
Total Debt
CLB
CLB
GLRE
GLRE
Q1 26
Q4 25
$110.3M
$4.7M
Q3 25
$114.1M
$34.7M
Q2 25
$124.6M
$58.9M
Q1 25
$124.4M
$59.8M
Q4 24
$126.1M
$60.7M
Q3 24
$139.9M
$62.6M
Q2 24
$147.6M
$61.6M
Stockholders' Equity
CLB
CLB
GLRE
GLRE
Q1 26
$275.1M
Q4 25
$266.0M
$708.0M
Q3 25
$271.3M
$658.9M
Q2 25
$261.3M
$663.3M
Q1 25
$253.4M
$666.8M
Q4 24
$246.6M
$635.9M
Q3 24
$250.7M
$663.4M
Q2 24
$240.3M
$634.0M
Total Assets
CLB
CLB
GLRE
GLRE
Q1 26
$587.7M
Q4 25
$584.0M
$2.2B
Q3 25
$591.4M
$2.1B
Q2 25
$602.1M
$2.2B
Q1 25
$591.5M
$2.2B
Q4 24
$585.1M
$2.0B
Q3 24
$600.5M
$2.0B
Q2 24
$597.8M
$1.9B
Debt / Equity
CLB
CLB
GLRE
GLRE
Q1 26
Q4 25
0.41×
0.01×
Q3 25
0.42×
0.05×
Q2 25
0.48×
0.09×
Q1 25
0.49×
0.09×
Q4 24
0.51×
0.10×
Q3 24
0.56×
0.09×
Q2 24
0.61×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
GLRE
GLRE
Operating Cash FlowLast quarter
$4.0M
$100.2M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.77×
2.03×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
GLRE
GLRE
Q1 26
$4.0M
Q4 25
$7.9M
$100.2M
Q3 25
$8.5M
$31.2M
Q2 25
$13.9M
$68.4M
Q1 25
$6.7M
$10.4M
Q4 24
$20.6M
$29.5M
Q3 24
$13.1M
$41.3M
Q2 24
$17.1M
$22.7M
Free Cash Flow
CLB
CLB
GLRE
GLRE
Q1 26
$517.0K
Q4 25
$5.0M
Q3 25
$6.5M
Q2 25
$10.4M
Q1 25
$3.9M
Q4 24
$17.4M
Q3 24
$10.4M
Q2 24
$14.3M
FCF Margin
CLB
CLB
GLRE
GLRE
Q1 26
0.4%
Q4 25
3.6%
Q3 25
4.8%
Q2 25
8.0%
Q1 25
3.1%
Q4 24
13.4%
Q3 24
7.7%
Q2 24
10.9%
Capex Intensity
CLB
CLB
GLRE
GLRE
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
2.7%
Q1 25
2.3%
Q4 24
2.5%
Q3 24
2.0%
Q2 24
2.2%
Cash Conversion
CLB
CLB
GLRE
GLRE
Q1 26
0.77×
Q4 25
1.61×
2.03×
Q3 25
0.60×
Q2 25
1.31×
208.02×
Q1 25
0.35×
Q4 24
2.78×
Q3 24
1.12×
1.17×
Q2 24
1.90×
2.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLB
CLB

Segment breakdown not available.

GLRE
GLRE

Other$124.7M59%
Innovations$85.6M41%

Related Comparisons